Boehringer Ingelheim Contract Development and Manufacturing Services for Biopharmaceuticals

The Boehringer Ingelheim Group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

Contract development and manufacture of biopharmaceuticals

Today, Boehringer Ingelheim is one of the world’s leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its manufacturing facilities for mammalian cell culture and microbial fermentation.

Boehringer Ingelheim has brought 18 molecules to market and has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products.

Contract manufacturing of mammalian cell culture products and biopharmaceuticals

Boehringer Ingelheim offers the entire production technology chain at its biopharmaceutical manufacturing facilities in Vienna (Austria), Fremont (US) and Biberach (Germany). It has the world’s largest capacities for contract development and manufacturing of mammalian cell culture products and is one of the leading manufacturers of biopharmaceuticals.

Boehringer Ingelheim’s experience: process development (including proprietary high-expression systems in CHO, E.coli and yeasts) and manufacturing of biopharmaceuticals such as therapeutic proteins, monoclonal antibodies, antibody fragments, protein scaffolds, and plasmid DNA for clinical trials and global market supply.

Boehringer Ingelheim’s services in biopharmaceuticals manufacturing include:

Mammalian cell culture

Features of Boehringer Ingelheim’s mammalian cell culture services:

  • Clinical material capacities: 80l to 2,000l
  • Production capacities: 6 x 2,000l to 2 x 12,000l and 12 x 15,000l
  • Fed-batch operations

Microorganism fermentation

Boehringer Ingelheim’s microorganism fermentation services include:

  • Clinical material capacities: 30l to 6,000l
  • Production capacities: 1 x 300l to 2 x 6,000l
  • Batch or fed-batch fermentation

Downstream processing services

Boehringer Ingelheim’s biopharmaceuticals manufacturing services include downstream processing services:

  • Multi-product purification suites
  • Explosion-proof unit and preparative HPLC
  • Viral inactivation procedures

Pharmaceutical manufacturing services

Boehringer Ingelheim’s expertise extends to pharmaceutical manufacturing:

  • Up to 150,000 vials per batch aseptic filling
  • Up to 100,000 syringes per batch aseptic filling
  • Up to 150,000 cartridges per batch aseptic filling

Opportunities for Boehringer Ingelheim’s partners

Boehringer Ingelheim’s wide-ranging capabilities and expertise offer many advantages for its partners, including:

  • One-stop-shop from DNA to final dosage form
  • Project start without initial investment
  • Supply of biopharmaceuticals up to large quantities
  • Worldwide-licensed multi-product facilities on safety level 1

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

Boehringer Ingelheim and VTU Technology Collaboration Benefits Customers with Broader Services

Boehringer Ingelheim, a global leader in biopharmaceutical contract development and manufacture, and VTU Technology, a leading supplier of exclusive technologies and comprehensive services for the development of high-performance Pichia pastoris protein expression strains, announced today that the

Boehringer Ingelheim Pharma GmbH & Co. KG

Binger Strasse 173

55216 Ingelheim am Rhein



+49 6132 77 0 +49 6132 72 0

Boehringer Ingelheim Images

Products and Services


White Papers

Related Projects

Boehringer Ingelheim’s Biopharmaceutical Production Facility in Vienna, Austria

Germany-based pharmaceutical company Boehringer Ingelheim is constructing a new large-scale cell culture (LSCC) facility at its site in Vienna, Austria.

5 October 2018

Boehringer Ingelheim’s New Tablet Production Facility, Ingelheim

Germany-based pharmaceutical company, Boehringer Ingelheim, is constructing a new tablet production facility in Ingelheim, Germany, with an estimated investment of more than €85m ($97.2m).

20 September 2018

Boehringer Ingelheim’s Integrated Asian Veterinary R&D Centre, Shanghai

Germany-based pharmaceutical company Boehringer Ingelheim’s veterinary research and development (R&D) centre is located within its research and development (R&D) site in Shanghai, China.

17 August 2018

Boehringer Ingelheim Biologicals Development Centre (BDC), Biberach, Germany

Boehringer Ingelheim is developing a new biologicals development centre (BDC) within its Biberach plant site in Germany.

29 June 2018

Lonza Houston’s Biotech Facility, Pearland, Texas

In April 2018, viral and cell therapy manufacturer Lonza Houston completed constructing a new biotech facility for immunotherapy development and manufacturing in Pearland, Texas, US.

15 June 2018

Samsung BioLogics’ Third Manufacturing Facility, Songdo

On 21 December 2015, Samsung BioLogics began constructing its third plant in Songdo, South Korea.

1 June 2018

Takeda Pharmaceutical’s High-Containment Production Facility, Grange Castle, Dublin

Japan-based pharmaceutical company Takeda has initiated construction of a new high-containment production facility at its existing site in Grange Castle Business Park in Dublin, Ireland.

12 July 2017

Boehringer Ingelheim Research Institute of Molecular Pathology (IMP)

The construction of a new research premises for the Research Institute of Molecular Pathology (IMP) began in March 2015 at the Vienna Biocenter in the third district of Vienna, Austria.

4 April 2017

Boehringer Ingelheim’s US Headquarters

Germany-based privately held pharmaceutical company Boehringer Ingelheim is involved in drug discovery, development and manufacturing.

1 April 2015

Press Release

12 September 2011

Boehringer Ingelheim has received the '2011 European Bio Pharmaceutical Contract Manufacturing Competitive Strategy Leadership Award' from Frost & Sullivan. The analysts recognised Boehringer Ingelheim Biopharmaceuticals as a global contract manufacturer that delivers excellence an

Read more
9 August 2011

Boehringer Ingelheim and ProBioGen have announced that they have signed a non-exclusive licensing agreement regarding ProBioGen's GlymaxX® technology. Boehringer Ingelheim's Contract Manufacturing Business will apply the technology to enhance ADCC (antibody-dependent cell-mediated cytotoxici

Read more
19 June 2011

To round off its full-service capabilities for clients, Boehringer Ingelheim is expanding its capacities and capabilities in fill and finish for biopharmaceuticals at its state-of-the-art facility in Biberach, Germany, with a new filling line. The new line is available as of today for contract f

Read more
30 May 2011

Boehringer Ingelheim has announced the US-registration for manufacturing of Bayer HealthCare's Betaferon® against multiple sclerosis. Recently Bayer HealthCare has extended the commercial production agreement for Betaferon with Boehringer Ingelheim, which received the FDA approval for Betafe

Read more
14 February 2011

Pfenex, an industry leader in protein expression through the Pfenex Expression Technology™ platform, and Boehringer Ingelheim International, a leading pharmaceutical company and global leader in biopharmaceutical contract development and manufacture, announced today that th

Read more
10 November 2010

Boehringer Ingelheim, a global leader in biopharmaceutical contract development and manufacture, and VTU Technology, a leading supplier of exclusive technologies and comprehensive services for the development of high-performance Pichia pastoris protein expression strains, announced today that the

Read more

Regional Offices

Boehringer Ingelheim Pharma GmbH & Co. KG

Binger Strasse 173

55216 Ingelheim am Rhein



+49 6132 77 0 +49 6132 72 0

Contact company

I have read and accept the terms and conditions and privacy policys.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.

Go Top